#United States #New York #Levi & Korsinsky #ARS Pharmaceuticals #SPRY

ARS Pharmaceuticals Faces a Shareholder Class Action

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is currently under scrutiny as a securities class action has been initiated, reminding investors who purchased shares between March 9, 2026, and June 24, 2026, of their potential eligibility for recovery. The law firm Levi & Korsinsky, LLP is leading this class action, which follows a dramatic 23.9% plunge in share prices, falling from $10.54 to $8.02 per share after the company's announcement on June 24, 2026.

Background on the Case

The class action stems from a sequence of disclosures made by ARS Pharmaceuticals concerning their product neffy and its coverage by CVS Caremark. During an earnings call on March 9, 2026, management conveyed high expectations for the drug's coverage, stating that an expansion was anticipated by July 1, 2026. This optimism set the stage for investor expectations over the following months.

On May 15, 2026, the company reportedly submitted proposals to include neffy in CVS's commercial formularies. This was seen as a pivotal development that falsely reassured investors regarding the timeline for coverage. However, when an announcement on June 24 revealed that no new coverage decisions for neffy were made for the July 1 cycle, shares of SPRY plummeted significantly by $2.52 per share.

Timeline of Events

• - March 9, 2026: Initial positive expectations for CVS coverage are set during an earnings call.
• - May 15, 2026: An updated proposal for neffy is submitted, reinforcing the anticipated timeline.
• - June 24, 2026: The company's stunning announcement comes after market close, revealing that coverage decisions are delayed until January 2027.

As a result of these events, the stock, which had been buoyed by investor faith in a timely resolution for expansion, faced a rapid decline. With around 99.3 million shares outstanding, this significant decrease in value raised red flags about the company's communications and whether they adequately informed investors of the risks.

Legal Implications

Joseph E. Levi, Esq. points out that the complaint questions the integrity of the information provided to investors regarding the CVS Caremark formulary timeline. The critical issue is whether adequate disclosures were made concerning the risks surrounding the delay in coverage.

The class action is filed in the United States District Court for the Southern District of California, under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Shareholders who feel affected by this downturn may want to gather pertinent brokerage documents to review their holdings during this class period.

Frequently Asked Questions

Q: How much did SPRY stock decline?
A: The stock dropped approximately 23.9%, equating to a $2.52 decrease in share price.

Q: What are the claims of the lawsuit?
A: The filing alleges ARS Pharmaceuticals misrepresented coverage timelines, which led to significant financial losses when the truth surfaced.

Q: What actions should investors take?
A: Investors are urged to contact Levi & Korsinsky for a free evaluation and gather relevant trading records to ascertain their eligibility for compensation.

Q: If I sold my shares, can I still recover my losses?
A: Yes, if you purchased shares during the class period and experienced losses, you may still be able to participate in any recovery.

The situation remains fluid, and affected shareholders are encouraged to stay informed. For more information, contact Levi & Korsinsky at (212) 363-7500 or via email at [email protected].

Conclusion

ARS Pharmaceuticals' recent challenges underscore the importance of transparency in corporate disclosures and the implications for investors. As more details unfold, shareholders must remain vigilant and proactive in protecting their interests.